SG10201909382UA - Glyt1 inhibitors for use in the treatment of hematological disorders - Google Patents
Glyt1 inhibitors for use in the treatment of hematological disordersInfo
- Publication number
- SG10201909382UA SG10201909382UA SG10201909382UA SG10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA SG 10201909382U A SG10201909382U A SG 10201909382UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- hematological disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Abstract
GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS The invention is related to compounds, which are GlyT1 inhibitors, for use in the treatment of hematological disorders, in particular for use in the treatment of sickle cell disease and 5 thalassemia, or for the treatment of patients with iron overload syndromes, such as hereditary hemochromatosis. [No Suitable Figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201909382UA true SG10201909382UA (en) | 2019-11-28 |
Family
ID=50677958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909382U SG10201909382UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
| SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608397UA SG11201608397UA (en) | 2014-04-30 | 2015-04-27 | Glyt1 inhibitors for use in the treatment of hematological disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (en) |
| EP (1) | EP3137073B1 (en) |
| JP (1) | JP6283766B2 (en) |
| KR (1) | KR101869185B1 (en) |
| CN (1) | CN106163520B (en) |
| AR (1) | AR100209A1 (en) |
| CY (1) | CY1120508T1 (en) |
| ES (1) | ES2683184T3 (en) |
| HR (1) | HRP20181205T1 (en) |
| MA (1) | MA39927B1 (en) |
| MY (1) | MY189930A (en) |
| PH (1) | PH12016501784B1 (en) |
| PT (1) | PT3137073T (en) |
| RS (1) | RS57535B1 (en) |
| SG (2) | SG10201909382UA (en) |
| SI (1) | SI3137073T1 (en) |
| TR (1) | TR201809598T4 (en) |
| WO (1) | WO2015165842A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (en) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Use of glycine transporter 1 antagonists as central nervous analgesics |
| CU20200106A7 (en) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS |
| WO2021142329A1 (en) * | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| KR20230169982A (en) * | 2021-03-12 | 2023-12-18 | 디스크 메디슨, 인크. | Compositions and methods for treating anemia associated with ribosomal disorders |
| AU2022273051A1 (en) * | 2021-05-14 | 2023-12-07 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| AU2022283357A1 (en) * | 2021-05-27 | 2023-12-07 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
| WO2023235326A1 (en) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions and methods for treating hepatic porphyrias with glycine transport inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2297458T3 (en) * | 2003-08-11 | 2008-05-01 | F. Hoffmann-La Roche Ag | PIPERAZINE WITH OR-SUBSTITUTED PHENYLL GROUP AND ITS EMPLOYMENT AS GLYTI INHIBITORS. |
| JP4647670B2 (en) * | 2005-02-07 | 2011-03-09 | エフ．ホフマン−ラ ロシュ アーゲー | Heterocyclyl-substituted phenylmethanones as inhibitors of glycine transporter 1 |
-
2015
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/en active IP Right Grant
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/en unknown
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/en active Active
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/en active Active
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/en active Active
- 2015-04-27 PT PT157179169T patent/PT3137073T/en unknown
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/en active Active
- 2015-04-27 SI SI201530334T patent/SI3137073T1/en unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/en active Application Filing
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/en unknown
- 2015-04-27 RS RS20180897A patent/RS57535B1/en unknown
- 2015-04-28 AR ARP150101268A patent/AR100209A1/en unknown
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784B1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-07-25 HR HRP20181205TT patent/HRP20181205T1/en unknown
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017511385A (en) | 2017-04-20 |
| RS57535B1 (en) | 2018-10-31 |
| CY1120508T1 (en) | 2019-07-10 |
| AR100209A1 (en) | 2016-09-21 |
| MY189930A (en) | 2022-03-22 |
| EP3137073B1 (en) | 2018-06-06 |
| US20170042888A1 (en) | 2017-02-16 |
| PH12016501784A1 (en) | 2016-11-07 |
| ES2683184T3 (en) | 2018-09-25 |
| US9877963B2 (en) | 2018-01-30 |
| MA39927B1 (en) | 2018-09-28 |
| EP3137073A1 (en) | 2017-03-08 |
| CN106163520A (en) | 2016-11-23 |
| MA39927A (en) | 2017-03-08 |
| PH12016501784B1 (en) | 2016-11-07 |
| SG11201608397UA (en) | 2016-11-29 |
| HRP20181205T1 (en) | 2018-09-21 |
| JP6283766B2 (en) | 2018-02-21 |
| KR20160130517A (en) | 2016-11-11 |
| KR101869185B1 (en) | 2018-06-19 |
| PT3137073T (en) | 2018-07-27 |
| CN106163520B (en) | 2019-12-13 |
| TR201809598T4 (en) | 2018-07-23 |
| SI3137073T1 (en) | 2018-09-28 |
| WO2015165842A1 (en) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018236800B2 (en) | DNA-PK inhibitors | |
| SG10201909382UA (en) | Glyt1 inhibitors for use in the treatment of hematological disorders | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2016004068A8 (en) | Hydrogel compositions comprising encapsulated cells and methods of use thereof | |
| IN2015DN01156A (en) | ||
| SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| WO2014062720A3 (en) | Methods of treating cancer | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| IN2014DN10386A (en) | ||
| MX2015011898A (en) | Pyrazolo compounds and uses thereof. | |
| EA201692526A1 (en) | SUBSTITUTED [1,2,4] TRIAZOLE COMPOUNDS | |
| MY189912A (en) | Substituted xanthines and methods of use thereof | |
| NZ630615A (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| MA39710A (en) | Topical composition for use in the treatment of inflammatory bowel disease | |
| EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| MX2016003823A (en) | A selective inhibitor of phosphatidylinositol 3-kinase-gamma. | |
| EA201692289A1 (en) | SUBSTITUTED [1,2,4] TRIAZOL AND IMIDAZOL COMPOUNDS AS FUNGICIDES | |
| WO2013169631A3 (en) | Wnt protein signalling inhibitors | |
| PH12016500495A1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| WO2014186450A3 (en) | Highly potent inhibitors of porcupine | |
| MX363385B (en) | Treatment of sickle cell disease and inflammatory conditions. | |
| EP2964750A4 (en) | Methods and compositions for the treatment and/or prevention of type 1 diabetes | |
| EP2994156A4 (en) | Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases |